Annual ROE
-247.45%
-156.01%-170.61%
December 31, 2024
Summary
- As of March 15, 2025, TVTX annual return on equity is -247.45%, with the most recent change of -156.01% (-170.61%) on December 31, 2024.
- During the last 3 years, TVTX annual ROE has fallen by -177.28% (-252.64%).
- TVTX annual ROE is now -127.79% below its all-time high of 890.42%, reached on December 1, 2012.
Performance
TVTX ROE Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly ROE
-504.54%
-178.72%-54.85%
December 1, 2024
Summary
- As of March 15, 2025, TVTX quarterly return on equity is -504.54%, with the most recent change of -178.72% (-54.85%) on December 1, 2024.
- Over the past year, TVTX quarterly ROE has dropped by -437.36% (-651.03%).
- TVTX quarterly ROE is now -182.79% below its all-time high of 609.44%, reached on March 31, 2014.
Performance
TVTX Quarterly ROE Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
ROE Formula
ROE = Net Income
Shareholders Equity ✕ 100%
Shareholders Equity ✕ 100%
TVTX ROE Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | -170.6% | -651.0% |
| 3 y3 years | -252.6% | -651.0% |
| 5 y5 years | -355.8% | -651.0% |
TVTX ROE Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3-year | -252.6% | at low | -749.3% | at low |
| 5 y | 5-year | -355.8% | at low | -1597.1% | at low |
| alltime | all time | -127.8% | at low | -182.8% | at low |
Travere Therapeutics ROE History
| Date | Annual | Quarterly |
|---|---|---|
| Dec 2024 | -247.45%(+170.6%) | - |
| Dec 2024 | - | -504.54%(+54.9%) |
| Sep 2024 | - | -325.82%(+206.5%) |
| Jun 2024 | - | -106.30%(+13.5%) |
| Mar 2024 | - | -93.65%(+39.4%) |
| Dec 2023 | -91.44%(-43.4%) | -67.18%(+12.5%) |
| Sep 2023 | - | -59.71%(-76.5%) |
| Jun 2023 | - | -253.72%(+22.5%) |
| Mar 2023 | - | -207.05%(+20.5%) |
| Dec 2022 | -161.46%(+130.1%) | -171.80%(+39.8%) |
| Sep 2022 | - | -122.90%(+39.5%) |
| Jun 2022 | - | -88.09%(+31.8%) |
| Mar 2022 | - | -66.84%(+12.5%) |
| Dec 2021 | -70.17%(-10.5%) | -59.41%(-28.0%) |
| Sep 2021 | - | -82.56%(+6.3%) |
| Jun 2021 | - | -77.66%(-1.6%) |
| Mar 2021 | - | -78.93%(+19.1%) |
| Dec 2020 | -78.37%(+44.4%) | -66.28%(+122.9%) |
| Sep 2020 | - | -29.73%(-16.7%) |
| Jun 2020 | - | -35.70%(-14.3%) |
| Mar 2020 | - | -41.67%(-23.3%) |
| Dec 2019 | -54.29%(+61.6%) | -54.30%(+27.0%) |
| Sep 2019 | - | -42.74%(-10.2%) |
| Jun 2019 | - | -47.59%(+14.8%) |
| Mar 2019 | - | -41.47%(+22.6%) |
| Dec 2018 | -33.59%(+69.0%) | -33.82%(-9.8%) |
| Sep 2018 | - | -37.51%(+46.0%) |
| Jun 2018 | - | -25.70%(+14.6%) |
| Mar 2018 | - | -22.43%(+12.8%) |
| Date | Annual | Quarterly |
|---|---|---|
| Dec 2017 | -19.88%(+26.1%) | -19.88%(+18.9%) |
| Sep 2017 | - | -16.72%(-27.1%) |
| Jun 2017 | - | -22.94%(+1.3%) |
| Mar 2017 | - | -22.65%(+46.5%) |
| Dec 2016 | -15.76%(-117.7%) | -15.46%(+13.4%) |
| Sep 2016 | - | -13.63%(-137.1%) |
| Jun 2016 | - | 36.69%(+1.6%) |
| Mar 2016 | - | 36.11%(-46.2%) |
| Dec 2015 | 89.25%(-70.0%) | 67.14%(-16.6%) |
| Sep 2015 | - | 80.54%(-233.7%) |
| Jun 2015 | - | -60.22%(-334.8%) |
| Mar 2015 | - | 25.65%(-95.3%) |
| Dec 2014 | 297.81%(+69.2%) | 542.72%(-9.1%) |
| Sep 2014 | - | 597.36%(+0.6%) |
| Jun 2014 | - | 593.77%(-2.6%) |
| Mar 2014 | - | 609.44%(+62.9%) |
| Dec 2013 | 176.06%(-80.2%) | 374.16%(-21.2%) |
| Sep 2013 | - | 474.55%(+41.2%) |
| Jun 2013 | - | 336.19%(-41.2%) |
| Mar 2013 | - | 571.66%(+2335.7%) |
| Dec 2012 | 890.42%(+3697.1%) | - |
| Nov 2012 | - | 23.47%(+0.1%) |
| Aug 2012 | - | 23.44%(-1.1%) |
| May 2012 | - | 23.70%(-0.6%) |
| Feb 2012 | - | 23.85%(-0.1%) |
| Feb 2012 | 23.45%(-38.5%) | - |
| Nov 2011 | - | 23.88%(-13.6%) |
| Aug 2011 | - | 27.63%(-16.3%) |
| May 2011 | - | 33.00%(-13.5%) |
| Feb 2011 | 38.14% | 38.14% |
FAQ
- What is Travere Therapeutics annual return on equity?
- What is the all time high annual ROE for Travere Therapeutics?
- What is Travere Therapeutics annual ROE year-on-year change?
- What is Travere Therapeutics quarterly return on equity?
- What is the all time high quarterly ROE for Travere Therapeutics?
- What is Travere Therapeutics quarterly ROE year-on-year change?
What is Travere Therapeutics annual return on equity?
The current annual ROE of TVTX is -247.45%
What is the all time high annual ROE for Travere Therapeutics?
Travere Therapeutics all-time high annual return on equity is 890.42%
What is Travere Therapeutics annual ROE year-on-year change?
Over the past year, TVTX annual return on equity has changed by -156.01% (-170.61%)
What is Travere Therapeutics quarterly return on equity?
The current quarterly ROE of TVTX is -504.54%
What is the all time high quarterly ROE for Travere Therapeutics?
Travere Therapeutics all-time high quarterly return on equity is 609.44%
What is Travere Therapeutics quarterly ROE year-on-year change?
Over the past year, TVTX quarterly return on equity has changed by -437.36% (-651.03%)